A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 1, 2015, Pages 105-115

  Arcangeli, Giorgio ^a   Arcangeli, Stefano ^b   Strigari, Lidia ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Bladder sparing trimodality; Muscle invasive bladder cancer; Radio chemotherapy

Indexed keywords

CISPLATIN;

BLADDER INTACT SURVIVAL; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CYSTECTOMY; HUMAN; LOCAL FAILURE FREE SURVIVAL; META ANALYSIS; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SURVIVAL; SURVIVAL TIME; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION OF MUSCLE INFILTRATING BLADDER TUMOR; TREATMENT RESPONSE; CONSERVATIVE TREATMENT; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM INVASIVENESS; ORGAN SPARING TREATMENTS; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84926122345     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.11.007     Document Type: Review

References (42)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001, 19:666-675.
2. Bentzen S.M., Harari P.M., Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007, 4(3):172-180.
3. Efstathiou J.A., Spiegel D.Y., Shipley W.U., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012, 61:705-711.
4. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002, 20:3061-3071.
5. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analysis studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151(4):W65-W94.
6. Peyromaure M., Slama J., Beuzeboc P., et al. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology 2004, 63:73-77.
7. Housset M., Maulard C., Chretien Y., et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993, 11:2150-2157.
8. Khaufman D.S., Winter K.A., Shipley W.U., et al. Phase I-II RTOG study (9906) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, Paclitaxel, Cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy ad adjuvant chemotherapy. Urology 2009, 73:833-837.
9. Mitin T., Hunt D., Shipley W.U., et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial. Lancet Oncol 2013, 14:863-872.
10. Mokarim A., Uetani M., Hayashi N., et al. Combined intra-arterial chemotherapy in the treatment of bladder carcinoma. Cancer 1997, 80:1776-1785.
11. Retz M., Lehmann J., Tocha C., et al. Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma. Cancer 2000, 89:1089-1094.
12. Hagan M., Winter K.A., Kaufman D.S., et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using YURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003, 57:665-672.
13. Sabaa M.A., El-Gamal O.M., Abo-Elenen M., et al. Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol Oncol 2010, 28:14-20. (Sem Orig Invest).
14. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996, 14:119-126.
15. Fellin G., Graffer U., Bolner A., et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single institution phase II study. Br J Urol 1997, 80:44-49.
16. Zapatero A., De Vldales C.M., Arellano R., et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology 2012, 80:1056-1062.
17. Shipley W.U., Zietman A.L., Kaufman D.S., et al. Selective bladder preservation by trimodality therapy for patients with muscolaris propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital ad Radiation Therapy Oncology Group Experiences. Semin Radiat Oncol 2004, 15:36-41.
18. Shipley W.U., Kaufman D.S., Lee W.R., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998, 16:3576-3583.
19. Chen R.C., Shipley W.U., Efstathiou J.A., Zietman A.L. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw 2013, 11:952-960.
20. Miyanaga N., Akaza H., Hinotsu S., et al. Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. Jpn J Clin Oncol 2007, 37:852-857.
21. Lin C.C., Hsu C.H., Cheng J.C., et al. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2009, 75:442-448.
22. Arias F., Dominguez M.A., Martinez E., et al. Chemoradiotherapy for muscle-invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000, 47:373-378.
23. Caffo O., Fellin G., Graffer U., et al. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Cancer 2011, 117:1190-1196.
24. Lagrange J.L., Bascoul-Mollevi C., Geoffrois L., et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 2011, 79:172-178.
25. Hara T., Nishijima J., Miyachika Y., et al. Primary cT2 bladder cancer: a good candidate for radiotherapy combined with cisplatin for bladder preservation. Jpn J Clin Oncol 2011, 41:902-907.
26. Hashine K., Kusuhara Y., Miura N., et al. Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer. Jpn J Clin Oncol 2009, 39:381-386.
27. Given R.W., Parsons J.T., McCarley D., Wajsman Z. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 1995, 46:499-505.
28. Choudhury A., Swindell R., Logue J.P., et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011, 29:733-738.
29. Ott O.J., Rodel C., Weiss C., et al. Radiochemotherapy for bladder cancer. Clin Oncol 2009, 21:557-565.
30. Hussain S.A., Stoken D.D., Glaholm J.G., et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004, 90:2106-2111.
31. Eapen L., Stewart D., Collins J., Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 2004, 172:1276-1280.
32. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. New Engl J Med 2012, 366:1477-1488.
33. Gogna N.K., Matthews J.H.L., Turner S.L., et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localized muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from Trans Tasman Radiation Oncology Group. Radiother Oncol 2006, 81:9-17.
34. Kragelj B., Zaletel-Kragelj L., Sedmak B., et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 2005, 75:44-47.
35. Tunio M.A., Hashmi A., Qayyum A., et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys 2012, 82:e457-e462.
36. Radosevic-Jelic L., Pekmezovic T., Pavlovic-Cvwtkovic L., et al. Concomitant radiotherapy and carboplatin in locally advanced bladder cancer. Eur Urol 1999, 36:401-405.
37. Perdonà S., Autorino R., Damiano R., et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer. A multi-institutional, long-term experience. Cancer 2008, 112:75-83.
38. Tirindelli-Danesi D., Arcangeli G., Cruciani E., et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy. Cancer 2004, 101:2540-2548.
39. Gamal El-Deen HSh, Elshazly H.F., Abo Zeina E.A. Clinical experience with radiotherapy alone and radiochemotherapy with platin based regimens in organ-sparing treatment of invasive bladder cancer. J Egypt Natl Canc Inst 2009, 21:59-70.
40. Shipley W.U., Kaufman D.S., Zehr E., Heney N.M., Lane S.C., Thakral H.K., et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002, 60(Jul (1)):62-67. (discussion 67-8).
41. George L., Bladou F., Bardou V.J., et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 2004, 64:488-493.
42. Advanced Bladder Cancer Overview Collaboration Neoadjuvant chemotherapy in invasive bladder cancer 2008, John Wiley & Sons, Ltd., Chichester, UK, (Cochrane Library; Issue 2), Available at http://www.uptdate-software.com.